Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Timon Vandamme

Has grant

Assistant Professor

University of Antwerp

Belgium

Research Interests

Explore related searches

Professors in Belgium Professors in Immunology Immunology professors in Belgium

Recent Grants

Grant: Close

Unlocking the potential of WT1 dendritic cell vaccination through IL15 transpresentation in pancreatic cancer patients.

Open Date: 2025-07-01

Close Date:

Grant: Close

Het mucine mRNA isovorm landschap en de alternatieve splicing machinerie bij colorectale kanker (MUCCOR): een nieuw paradigma in de verstoring van tumorceldood.

Open Date: 2025-01-01

Close Date:

Grant: Close

Verbetering behandeling van pancreatische neuro-endocriene tumoren door karakterisering van de moleculaire mechanismen die tumorgedrag beïnvloeden m.b.v. multi-omics en identificatie van prognostische biomerkers via een machine-learning benadering.

Open Date: 2025-01-01

Close Date:

Grant: Close

Detectie van FGFR2 fusies in cholangiocarcinoompatiënten met een nieuw singlet zuurstof gebaseerd fotoëlektrochemisch platform.

Open Date: 2024-11-01

Close Date:

Grant: Close

MutArray: Een CRISPR/Cas-aangedreven foto-elektrochemisch bioplatform voor de detectie van single nucleotide variaties geassocieerd met colorectale kanker.

Open Date: 2024-10-01

Close Date:

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (22)

Martin Bartosik

Masaryk Memorial Cancer Institute

CZECH REPUBLIC

Timon Vandamme

Research Interests

Explore related searches

Recent Grants

Articles (20)

The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients

Clamp the LAMP: a photoelectrochemical platform for KRAS mutation detection via wild-type blocking

Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy

Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients.

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative

Bridging the gap

Prognosis in stage II colorectal cancer: the effect of the primary tumor location and biomarkers—a retrospective cohort study

mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies

Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors

Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer

Comparison of inter- and intraobserver agreement between [¹⁸F]AlF-NOTA-octreotide and [⁶⁸Ga]Ga-DOTA-SSA PET/CT

Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms - experience from NETwerk, a Belgian ENETS Center of Excellence

Management of high-grade neuroendocrine neoplasms

Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer

Rationale and design of the COPERNIC trial

Reply to letter comments on

STRONG II trial

Collaborators (22)

Martin Bartosik

Elke Smits

Léon van Kempen

Sara De Dosso

Clara Montagut Viladot

Christof Vulsteke

Erik van Werkhoven

Marc Peeters

Emmanuel Deshayes

Hans Prenen

Ann De Becker

Jenny Seligmann

Oleg Rudenko

Michele Ghidini

Remond J.A. Fijneman

Frederik Cleeren

Emerik Osterlund

Yvette Seppenwoolde

Paula Jimenez-Fonseca

Steven Abrams

Karen-Lise Garm Spindler

Pia Osterlund

Make your next move.